Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14366653 | 1.00 | CTSK (0.50) | CTSKCTSLCTSBCTSSPREP | |
| SCHEMBL10345811 | 1.00 | CTSK (0.50) | CTSKCTSLCTSBCTSSPREP | |
| SCHEMBL10354168 | 0.95 | CTSK (0.51) | CTSKCTSLCTSBCTSSPREP | |
| SCHEMBL10357140 | 0.88 | CTSB (0.53) | CTSKCTSLCTSBCTSSMEN1 | |
| SCHEMBL4425151 | 0.88 | CTSB (0.53) | CTSKCTSLCTSBCTSSMEN1 | |
| SCHEMBL4039888 | 0.88 | CTSB (0.53) | CTSKCTSLCTSBCTSSMEN1 | |
| SCHEMBL20529553 | 0.87 | CTRB1 (0.48) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL10975944 | 0.87 | ATM (0.46) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL25933042 | 0.87 | CYP3A4 (0.48) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL10975947 | 0.87 | ATM (0.46) | CTSKCTSLCTSBCTSSATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113774513-A | Preparation method of cashmere blended product with fatigue resistance | 江南织造府(宁波)线业有限公司 | 2021-12-10 | — | — | CN | claimed |
| EP-3810615-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4619037-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-12173018-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4426729-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| EP-4426741-A1 | BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE | Hangzhou DAC Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-12054501-B2 | Compositions and methods for inhibiting arginase activity | PRECISION PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2024105197-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | VINCERX PHARMA GMBH (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | US | disclosed |
| EP-0043247-A1 | Peptides for use in determining serum thymic factor | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1982-01-06 | — | — | EP | disclosed |
| US-4264590-A | DIPEPTIDE OF A HALOALANINE | ABBOTT LABORATORIES (US) | 1981-04-28 | — | — | US | disclosed |
| EP-0020481-A4 | ANTIBACTERIAL PEPTIDE. | ABBOTT LAB (US) | 1981-04-24 | — | — | EP | disclosed |
| US-4250085-A | PHOSPHONATE-CONTAINING OLIGOPEPTIDES, BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1981-02-10 | — | — | US | disclosed |
| EP-0020481-A1 | ANTIBACTERIAL PEPTIDE | ABBOTT LABORATORIES (US) | 1981-01-07 | — | — | EP | disclosed |
| WO-1980000789-A1 | ANTIBACTERIAL PEPTIDE | ABBOTT LAB (US) | 1980-05-01 | — | — | WO | disclosed |
| US-4187216-A | ELASTASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1980-02-05 | — | — | US | disclosed |
| US-4176116-A | ELASTASE ENZYME INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1979-11-27 | — | — | US | disclosed |
| EP-0002822-A1 | Phosphorus containing peptide derivatives, their production, intermediates for their production and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-07-11 | — | — | EP | disclosed |
| US-4064270-A | ANTHELMINTICS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054501-B2 | Compositions and methods for inhibiting arginase activity | ARG1, ARG2, PRMT3 | CTSK 464/4885CTSL 634/4885CTSB 219/4885 |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | CTSK 378/4885CTSL 357/4885CTSB 245/4885 |
| US-12173018-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | CTSK 2792/4885CTSL 494/4885CTSB 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.